Frederick Hausheer, M.D., a medical oncologist, founded BioNumerik to discover and develop innovative oncology drugs by merging medicine, quantum and statistical mechanics, pharmaceutical development and supercomputing. Dr. Hausheer, a recognized expert in drug discovery, pharmacology, clinical drug development and pharmaceutical application software and supercomputing development, decided to launch BioNumerik after observing the traditional methods of drug discovery and development and becoming frustrated with the lack of effective and less toxic anti-cancer drugs available to treat patients.
Dr. Hausheer created the company's name to reflect the combination of basic biology, biochemistry, biophysics, bioinformatics and biomedicine (Bio) with supercomputing power that is largely based on numerically intensive high-level computation (Numerik).
Based in San Antonio, Texas, BioNumerik is focused on the discovery, development and commercialization of novel drugs for the treatment of cancer and cancer supportive care. BioNumerik currently has two self-originated candidates, Tavocept® and Karenitecin® in late-stage clinical development. BioNumerik has multiple additional oncology research programs, and has generated a patent portfolio of more than 470 patents and pending patent applications worldwide.
BioNumerik’s management team and scientific advisors include experienced professionals who have substantial scientific, business, clinical and regulatory experience.